No abstract

No abstract

Large area reduced graphene oxide (RGO) thin films have been grown using pulsed laser deposition (PLD) technique. A very large carrier mobility of 372 cm 2 V -1 s -1 has been observed in a PLD grown RGO thin film with a large sp 2 carbon fraction of 87% along with narrow Raman 2D peak profile. The fraction of sp 2 carbon and carbon/oxygen ratios are tuned through PLD growth parameters, and these are estimated from X-ray photoelectron spectroscopy (XPS) data. The electrical properties of the RGO thin films are comprehended by the intensity ratios between different optical phonon vibrational modes of Raman Spectra. The photoluminescence spectra also indicate a less intense and broader blue fluorescence spectrum detecting the presence of miniature sized sp 2 domains in the near vicinity of π* electronic states which favor the variable range hopping transport phenomena. This study on large area RGO thin films with very large carrier mobility fabricated by PLD process will be very useful for high mobility electronic device applications and could open a roadmap for further extensive research in functionalized 2D materials.

The aim of this study was to investigate the distribution, tolerance, and anticancer and antiviral activity of Zn-based physiometacomposites (PMCs). Manganese, iron, nickel and cobalt-doped ZnO, ZnS or ZnSe were synthesized. Cell uptake, distribution into 3D culture and mice, and biochemical and chemotherapeutic activity were studied by fluorescence/bioluminescence, confocal microscopy, flow cytometry, viability, antitumor and virus titer assays. Luminescence and inductively coupled plasma mass spectrometry analysis showed that nanoparticle distribution was liver >spleen >kidney >lung >brain, without tissue or blood pathology. Photophysical characterization as ex vivo tissue probes and LL37 peptide, antisense oligomer or aptamer delivery targeting RAS/Ras binding domain (RBD) was investigated. Treatment at 25 μg/ml for 48 h showed ≥98–99% cell viability, 3D organoid uptake, 3-log inhibition of β-Galactosidase and porcine reproductive respiratory virus infection. Data support the preclinical development of PMCs for imaging and delivery targeting cancer and infectious disease.

No abstract